Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMW8X05)

Drug Name

THR-149 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Diabetic macular edema	9B71.02	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Plasma kallikrein (KLKB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ecallantide	DMOF2C6	Retina venous occlusion	9B74.1	Approved	[3]
Lanadelumab	DMEH7YU	Hereditary angioedema	4A00.14	Approved	[4]
Berotralstat	DMWA2DZ	Hereditary angioedema	4A00.14	Approved	[5]
KVD001	DMK4VOU	Diabetic macular edema	9B71.02	Phase 2	[6]
KVD824	DM5N4OA	Diabetic macular edema	9B71.02	Phase 2	[7]
(4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone	DM31OSD	Discovery agent	N.A.	Investigative	[8]
(3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone	DMT9FZD	Discovery agent	N.A.	Investigative	[8]
1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide	DMG5MNZ	Discovery agent	N.A.	Investigative	[8]
D-Pro-Phe-Arg chloromethyl ketone	DMRJQ8X	Discovery agent	N.A.	Investigative	[9]
(3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone	DMNVDLI	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT04527107) A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema (KALAHARI). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Oxurion.
3	Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99.
4	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Clinical pipeline report, company report or official report of KalVista Pharmaceuticals.
8	N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38.
9	Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80.